Blackstone and TPG revive interest in buying Hologic, source says

Private equity firms Blackstone and TPG have reportedly revived their interest in acquiring medical device maker Hologic, following the company's rejection of a $16 billion non-binding offer from the private equity firms in May. This renewed pursuit signals continued private equity appetite for Hologic, potentially reigniting acquisition talks and impacting its market valuation.

Analysis

Renewed acquisition interest in medical device maker Hologic (HOLX) by private equity firms Blackstone (BX) and TPG (TPG) signals a high probability of continued M&A activity surrounding the company. This development follows Hologic's rejection of a $16 billion non-binding offer from the same firms in May, establishing a potential valuation floor for future negotiations and indicating the board's confidence in a higher intrinsic value. The persistence from two major private equity players underscores a strong conviction in Hologic's assets. While the report remains speculative, the positive sentiment score for Hologic (0.6) reflects market anticipation of a potential bid premium, suggesting the company is now firmly 'in play'.

Key Decisions for Investors

• Investors holding Hologic (HOLX) should consider the increased likelihood of a takeover offer, as the revived interest establishes a potential valuation floor and could unlock value through an acquisition premium.
• The situation presents an event-driven opportunity, but investors must weigh the potential for a higher bid against the risk that negotiations fail to result in a definitive agreement, which could cause the share price to retreat.
• For investors in Blackstone (BX) and TPG (TPG), this potential transaction reinforces their strategic focus on large-scale buyouts in the resilient healthcare sector, signaling continued aggressive capital deployment.